EUVIMEDEUVIMED entdecken
Crossref

Prospective study on tumor control, survival, toxicity and quality of life after EBRT and an HDR-brachytherapy boost in intermediate to high-risk prostate cancer patients

Max Peters, Tonnis T Nuver, Marnix J A Rasing, Margo C Noordhoek, Marie A D Haverkort, Erik C Schimmel, Wout J Schoevers, Michal D Czerwinski, Peter S N van Rossum, Robert A J Kattevilder, André W Minken

Brachytherapy · 2026

DOI: 10.1016/j.brachy.2025.12.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brachytherapy, 2026. Verfasst von Max Peters und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Radiotherapiegroep, Deventer/Arnhem, the Netherlands; Department of Radiation Oncology, University Medical Center U…. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Brachytherapy, Quality of Life. Die Arbeit nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Brachytherapy boost improves biochemical disease-free survival (bDFS) for intermediate/high-risk prostate cancer, but may increase toxicity. We prospectively assessed tumor control, survival, toxicity, and quality of life (QoL) in a large cohort treated with high-dose-rate (HDR) brachytherapy boost after hypo-fractionated external beam radiotherapy (EBRT) and assessed predictors for tumor control and survival. METHODS AND MATERIALS: From 2010 to 2020 patients received EBRT (58 Gy in 20 fractions to prostate/seminal vesicles or 62.5 Gy in 25 fractions with 50 Gy to pelvic nodes), followed by a 10 Gy HDR brachytherapy boost, and androgen deprivation therapy (ADT) up to 3 years. Biochemical recurrence was defined by the Phoenix criterion. Toxicity (CTCAE v3.0) and QoL (IPSS, Likert scales for bowel and erectile function) were prospectively recorded. Outcomes were analyzed using Kaplan-Meier analysis and Cox/competing-risk models. RESULTS: Among 274 patients (267 high risk), median follow-up was 95 months. Eight-year bDFS and overall survival (OS) were both 76%, and prostate cancer-specific survival (PCASS) 95%. PSA nadir > 0.1 ng/mL was the strongest predictor for biochemical failure and PCASS (8-year bDFS: 88% vs. 31%, p < 0.001). Longer time to PSA nadir improved tumor control and survival. Late Grade 3 genitourinary toxicity occurred in 4.4% and gastrointestinal in 0.7%. Median IPSS increased from 7 to maximum 10 (p < 0.001), minor bowel symptoms from 3% to maximum 13%. Complete erectile dysfunction rose from 18% to maximum 47% (p < 0.001). CONCLUSION: EBRT with ADT and HDR brachytherapy boost provides durable tumor control with acceptable long-term toxicity. PSA nadir and time to nadir are strong predictors for outcomes and may support personalized follow-up strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsBrachytherapyQuality of LifeMaleHumansProspective StudiesAgedMiddle AgedAged, 80 and overDisease-Free Survival

Stichwörter der Autor:innen

HDR boostPredictive factorsProstate cancer

Autor:innen und Institutionen

  • Department of Radiation Oncology, Radiotherapiegroep, Deventer/Arnhem, the Netherlands; Department of Radiation Oncology, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands. Electronic address: max.peter…
  • Department of Radiation Oncology, Radiotherapiegroep, Deventer/Arnhem, the Netherlands.
  • Department of Radiation Oncology, Radiotherapiegroep, Deventer/Arnhem, the Netherlands; Department of Radiation Oncology, University Medical Center Utrecht (UMCU), Utrecht, the Netherlands.
  • Department of Radiation Oncology, Amsterdam UMC, Amsterdam, the Netherlands.

Zitieren

APA

Peters, M., Nuver, T. T., Rasing, M. J. A., Noordhoek, M. C., Haverkort, M. A. D., Schimmel, E. C., Schoevers, W. J., Czerwinski, M. D., van Rossum, P. S. N., Kattevilder, R. A. J., & Minken, A. W. (2026). Prospective study on tumor control, survival, toxicity and quality of life after EBRT and an HDR-brachytherapy boost in intermediate to high-risk prostate cancer patients. Brachytherapy. https://doi.org/10.1016/j.brachy.2025.12.003

Vancouver

Peters M, Nuver TT, Rasing MJA, Noordhoek MC, Haverkort MAD, Schimmel EC, et al. Prospective study on tumor control, survival, toxicity and quality of life after EBRT and an HDR-brachytherapy boost in intermediate to high-risk prostate cancer patients. Brachytherapy. 2026. doi:10.1016/j.brachy.2025.12.003

BibTeX
@article{Peters2026,
  author = {Peters, Max and Nuver, Tonnis T and Rasing, Marnix J A and Noordhoek, Margo C and Haverkort, Marie A D and Schimmel, Erik C and Schoevers, Wout J and Czerwinski, Michal D and van Rossum, Peter S N and Kattevilder, Robert A J and Minken, André W},
  title = {Prospective study on tumor control, survival, toxicity and quality of life after EBRT and an HDR-brachytherapy boost in intermediate to high-risk prostate cancer patients},
  journal = {Brachytherapy},
  year = {2026},
  doi = {10.1016/j.brachy.2025.12.003}
}
Kostenlos starten →